272 related articles for article (PubMed ID: 37520560)
1. Cancer-associated fibroblasts drive CXCL13 production in activated T cells via TGF-beta.
O'Connor RA; Martinez BR; Koppensteiner L; Mathieson L; Akram AR
Front Immunol; 2023; 14():1221532. PubMed ID: 37520560
[TBL] [Abstract][Full Text] [Related]
2. TGF-β induces the differentiation of human CXCL13-producing CD4(+) T cells.
Kobayashi S; Watanabe T; Suzuki R; Furu M; Ito H; Ito J; Matsuda S; Yoshitomi H
Eur J Immunol; 2016 Feb; 46(2):360-71. PubMed ID: 26541894
[TBL] [Abstract][Full Text] [Related]
3. Tumoral and stromal hMENA isoforms impact tertiary lymphoid structure localization in lung cancer and predict immune checkpoint blockade response in patients with cancer.
Di Modugno F; Di Carlo A; Spada S; Palermo B; D'Ambrosio L; D'Andrea D; Morello G; Belmonte B; Sperduti I; Balzano V; Gallo E; Melchionna R; Panetta M; Campo G; De Nicola F; Goeman F; Antoniani B; Carpano S; Frigè G; Warren S; Gallina F; Lambrechts D; Xiong J; Vincent BG; Wheeler N; Bortone DS; Cappuzzo F; Facciolo F; Tripodo C; Visca P; Nisticò P
EBioMedicine; 2024 Mar; 101():105003. PubMed ID: 38340557
[TBL] [Abstract][Full Text] [Related]
4. PD-1
Li JP; Wu CY; Chen MY; Liu SX; Yan SM; Kang YF; Sun C; Grandis JR; Zeng MS; Zhong Q
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34253636
[TBL] [Abstract][Full Text] [Related]
5. Intratumoral CXCL13
Dai S; Zeng H; Liu Z; Jin K; Jiang W; Wang Z; Lin Z; Xiong Y; Wang J; Chang Y; Bai Q; Xia Y; Liu L; Zhu Y; Xu L; Qu Y; Guo J; Xu J
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589528
[TBL] [Abstract][Full Text] [Related]
6. CXCL13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer.
Yang M; Lu J; Zhang G; Wang Y; He M; Xu Q; Xu C; Liu H
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33452206
[TBL] [Abstract][Full Text] [Related]
7. Tertiary lymphoid structures marker CXCL13 is associated with better survival for patients with advanced-stage bladder cancer treated with immunotherapy.
Groeneveld CS; Fontugne J; Cabel L; Bernard-Pierrot I; Radvanyi F; Allory Y; de Reyniès A
Eur J Cancer; 2021 May; 148():181-189. PubMed ID: 33743486
[TBL] [Abstract][Full Text] [Related]
8. CXCL13-producing CD4+ T cells accumulate in the early phase of tertiary lymphoid structures in ovarian cancer.
Ukita M; Hamanishi J; Yoshitomi H; Yamanoi K; Takamatsu S; Ueda A; Suzuki H; Hosoe Y; Furutake Y; Taki M; Abiko K; Yamaguchi K; Nakai H; Baba T; Matsumura N; Yoshizawa A; Ueno H; Mandai M
JCI Insight; 2022 Jun; 7(12):. PubMed ID: 35552285
[TBL] [Abstract][Full Text] [Related]
9. Integrative analyses of bulk and single-cell RNA-seq identified cancer-associated fibroblasts-related signature as a prognostic factor for immunotherapy in NSCLC.
Wang S; Fan G; Li L; He Y; Lou N; Xie T; Dai L; Gao R; Yang M; Shi Y; Han X
Cancer Immunol Immunother; 2023 Jul; 72(7):2423-2442. PubMed ID: 37010552
[TBL] [Abstract][Full Text] [Related]
10. An imbalance between blood CD4
Cao G; Wang P; Cui Z; Yue X; Chi S; Ma A; Zhang Y
Mol Immunol; 2020 Sep; 125():1-8. PubMed ID: 32610164
[TBL] [Abstract][Full Text] [Related]
11. CXCL13-mediated recruitment of intrahepatic CXCR5
Li Y; Tang L; Guo L; Chen C; Gu S; Zhou Y; Ye G; Li X; Wang W; Liao X; Wang Y; Peng X; Liu G; Zhang X; Sun J; Peng J; Hou J
J Hepatol; 2020 Mar; 72(3):420-430. PubMed ID: 31610223
[TBL] [Abstract][Full Text] [Related]
12. Immune mechanisms orchestrate tertiary lymphoid structures in tumors via cancer-associated fibroblasts.
Rodriguez AB; Peske JD; Woods AN; Leick KM; Mauldin IS; Meneveau MO; Young SJ; Lindsay RS; Melssen MM; Cyranowski S; Parriott G; Conaway MR; Fu YX; Slingluff CL; Engelhard VH
Cell Rep; 2021 Jul; 36(3):109422. PubMed ID: 34289373
[TBL] [Abstract][Full Text] [Related]
13. Cancer-associated fibroblasts promote an immunosuppressive microenvironment through the induction and accumulation of protumoral macrophages.
Takahashi H; Sakakura K; Kudo T; Toyoda M; Kaira K; Oyama T; Chikamatsu K
Oncotarget; 2017 Jan; 8(5):8633-8647. PubMed ID: 28052009
[TBL] [Abstract][Full Text] [Related]
14. Single-cell and spatial transcriptomics reveal POSTN
Chen C; Guo Q; Liu Y; Hou Q; Liao M; Guo Y; Zang Y; Wang F; Liu H; Luan X; Liang Y; Guan Z; Li Y; Liu H; Dong X; Zhang X; Liu J; Xu Q
Clin Transl Med; 2023 Dec; 13(12):e1515. PubMed ID: 38115703
[TBL] [Abstract][Full Text] [Related]
15. Location of CD39
Koppensteiner L; Mathieson L; Pattle S; Dorward DA; O'Connor R; Akram AR
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37648263
[TBL] [Abstract][Full Text] [Related]
16. T cells drive negative feedback mechanisms in cancer associated fibroblasts, promoting expression of co-inhibitory ligands, CD73 and IL-27 in non-small cell lung cancer.
O'Connor RA; Chauhan V; Mathieson L; Titmarsh H; Koppensteiner L; Young I; Tagliavini G; Dorward DA; Prost S; Dhaliwal K; Wallace WA; Akram AR
Oncoimmunology; 2021; 10(1):1940675. PubMed ID: 34290905
[TBL] [Abstract][Full Text] [Related]
17. Distinct exhaustion features of T lymphocytes shape the tumor-immune microenvironment with therapeutic implication in patients with non-small-cell lung cancer.
Kim CG; Kim G; Kim KH; Park S; Shin S; Yeo D; Shim HS; Yoon HI; Park SY; Ha SJ; Kim HR
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34907028
[TBL] [Abstract][Full Text] [Related]
18. IL-6 Secreted from Cancer-Associated Fibroblasts Mediates Chemoresistance in NSCLC by Increasing Epithelial-Mesenchymal Transition Signaling.
Shintani Y; Fujiwara A; Kimura T; Kawamura T; Funaki S; Minami M; Okumura M
J Thorac Oncol; 2016 Sep; 11(9):1482-92. PubMed ID: 27287412
[TBL] [Abstract][Full Text] [Related]
19. Tertiary lymphoid structures improve immunotherapy and survival in melanoma.
Cabrita R; Lauss M; Sanna A; Donia M; Skaarup Larsen M; Mitra S; Johansson I; Phung B; Harbst K; Vallon-Christersson J; van Schoiack A; Lövgren K; Warren S; Jirström K; Olsson H; Pietras K; Ingvar C; Isaksson K; Schadendorf D; Schmidt H; Bastholt L; Carneiro A; Wargo JA; Svane IM; Jönsson G
Nature; 2020 Jan; 577(7791):561-565. PubMed ID: 31942071
[TBL] [Abstract][Full Text] [Related]
20. NOX4 Inhibition Potentiates Immunotherapy by Overcoming Cancer-Associated Fibroblast-Mediated CD8 T-cell Exclusion from Tumors.
Ford K; Hanley CJ; Mellone M; Szyndralewiez C; Heitz F; Wiesel P; Wood O; Machado M; Lopez MA; Ganesan AP; Wang C; Chakravarthy A; Fenton TR; King EV; Vijayanand P; Ottensmeier CH; Al-Shamkhani A; Savelyeva N; Thomas GJ
Cancer Res; 2020 May; 80(9):1846-1860. PubMed ID: 32122909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
